Antitumor effects of a recombinant baculovirus displaying anti-HER2 scFv expressing Apoptin in HER2 positive SK-BR-3 breast cancer cells

Meysami, Parisa, Rezaei, Farhad, Marashi, Sayed Mahdi, Amiri, Mohammad Mehdi, Bakker, Emyr orcid iconORCID: 0000-0002-0091-1029 and Mokhtari-Azad, Talat (2019) Antitumor effects of a recombinant baculovirus displaying anti-HER2 scFv expressing Apoptin in HER2 positive SK-BR-3 breast cancer cells. Future Virology, 14 (3). ISSN 1746-0794

[thumbnail of Author Accepted Manuscript]
Preview
PDF (Author Accepted Manuscript) - Accepted Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

1MB

Official URL: https://doi.org/10.2217/fvl-2018-0187

Abstract

Aim: Since HER2 targeted therapies have shown clinical benefit in breast cancer, in the present study recombinant baculovirus (BV) displaying anti-HER2 single-chain variable domain fragment (scFv) expressing Apoptin was generated. Methods: The binding specificity and surface display of anti-HER2 scFv were evaluated using enzyme-linked immunosorbent andassay (ELISA) and electron microscopy, respectively. The targeting properties and cytotoxic effect on breast cancer cells determined by fluorescence microscopy and MTT assays. Results: The results demonstrated that recombinant BV could specifically bind to HER2-overexpressing SK-BR-3 cells but not to the HER2 negative MCF-7 cells and reduced the viability of SK-BR-3 cells by expressing Apoptin. Conclusion: These results suggest that the antitumor effect of Apoptin in combination with HER2 targeting of this recombinant BV makes it a promising vector in targeted cancer therapy


Repository Staff Only: item control page